"Viking Therapeutics is the most direct GLP-1 acquisition target in the sector, with its lead asset, VK2735, showing up to 12.2% body weight reduction in Phase 2."
"Structure Therapeutics is building a best-in-class oral GLP-1 franchise, with its lead asset, aleniglipron, achieving placebo-adjusted mean weight loss of 11.3% and 15.3% in Phase 2b."
The GLP-1 revolution is transforming biopharma M&A strategies, with Novo Nordisk and Eli Lilly leading in obesity drug revenues. Large-cap acquirers are seeking transformative assets, focusing on companies like Viking Therapeutics and Structure Therapeutics. Viking's VK2735 is a dual GLP-1/GIP receptor agonist with promising Phase 2 results and a strong Phase 3 program. Structure is developing a competitive oral GLP-1 franchise with its lead asset, aleniglipron, showing significant weight loss in trials. Both companies present compelling opportunities for acquirers looking to diversify their portfolios.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]